Status:
COMPLETED
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to assess the safety and tolerability of AZD3043 following administration of single ascending bolus doses (Part A) and single ascending bolus doses followed by inf...
Eligibility Criteria
Inclusion
- Subjects with suitable veins for cannulation or repeated venepuncture
- Pre-dose assessment judged without remarks by the investigator
- Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg
Exclusion
- Abnormal vital signs, after 15 minutes supine rest, defined as any of the following:
- Systolic blood pressure \>140 mm Hg
- Diastolic blood pressure \>90 mm Hg
- Heart rate ≤45 or \>85 beats per minute
- Lack of normal phenotype for BuChE (Butyrylcholinesterase)
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00984880
Start Date
September 1 2009
End Date
December 1 2009
Last Update
December 18 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Stockholm, Sweden